Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid

被引：0
|
作者：
Xinmin Zhao
Xiaofeng Xu
Qunling Zhang
Zhen Jia
Si Sun
Jian Zhang
Biyun Wang
Zhonghua Wang
Xichun Hu
机构：
[1] Fudan University,Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College
[2] Fudan University,Department of Clinical Laboratory, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College
来源：
BMC Cancer | / 11卷
关键词：
Advanced breast cancer; bone metastases; zoledronic acid; VEGF; N-telopeptide; prognosis; predictive factors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid
    Zhao, Xinmin
    Xu, Xiaofeng
    Zhang, Qunling
    Jia, Zhen
    Sun, Si
    Zhang, Jian
    Wang, Biyun
    Wang, Zhonghua
    Hu, Xichun
    BMC CANCER, 2011, 11
  • [2] Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid
    Coleman, RE
    Major, P
    Lipton, A
    Brown, JE
    Lee, KA
    Smith, M
    Saad, F
    Zheng, M
    Hei, YJ
    Seaman, J
    Cook, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 4925 - 4935
  • [3] Zoledronic acid for the prevention of bone metastases in patients with breast cancer
    Coleman, R.
    Gralow, J.
    Bell, R.
    Lipton, A.
    EJC SUPPLEMENTS, 2004, 2 (03): : 74 - 75
  • [4] Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance
    Zhao, Xinmin
    Xu, Xiaofeng
    Guo, Lin
    Ragaz, Joseph
    Guo, Haiyi
    Wu, Jiong
    Shao, Zhimin
    Zhu, Ji
    Guo, Xiaomao
    Chen, Jiayi
    Zhu, Beiling
    Wang, Zhonghua
    Hu, Xichun
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (03) : 733 - 743
  • [5] Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance
    Xinmin Zhao
    Xiaofeng Xu
    Lin Guo
    Joseph Ragaz
    Haiyi Guo
    Jiong Wu
    Zhimin Shao
    Ji Zhu
    Xiaomao Guo
    Jiayi Chen
    Beiling Zhu
    Zhonghua Wang
    Xichun Hu
    Breast Cancer Research and Treatment, 2010, 124 : 733 - 743
  • [6] Clinical outcome and prognostic factors in hepatocellular carcinoma patients with bone metastases medicated with zoledronic acid
    Honda, Yohji
    Aikata, Hiroshi
    Honda, Fumi
    Nakano, Norihito
    Nakamura, Yuki
    Hatooka, Masahiro
    Morio, Kei
    Kobayashi, Tomoki
    Fukuhara, Takayuki
    Nagaoki, Yuko
    Kawaoka, Tomokazu
    Hiramatsu, Akira
    Imamura, Michio
    Kawakami, Yoshiiku
    Chayama, Kazuaki
    HEPATOLOGY RESEARCH, 2017, 47 (10) : 1053 - 1060
  • [7] Quality of Life Assessment in Taiwanese Patients with Bone Metastases from Breast Cancer Receiving Zoledronic Acid
    Chao, Ta-Chung
    Chen, Dar-Ren
    Chao, Tsu-Yi
    Chen, Shin-Cheh
    Yeh, Dah-Cherng
    Wang, Hwei-Chung
    Huang, Wen-Tsung
    Rau, Kun-Ming
    Chang, King-Jen
    Yang, Tsen-Long
    Lee, Kuan-Der
    Tai, Cheng-Jeng
    Tseng, Ling-Ming
    Hou, Ming-Feng
    ANTICANCER RESEARCH, 2013, 33 (12) : 5543 - 5547
  • [8] Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid
    Pectasides, D
    Nikolaou, M
    Farmakis, D
    Kanakis, I
    Gaglia, A
    Kountourakis, P
    Karamanos, NK
    Economopoulos, T
    Raptis, SA
    ANTICANCER RESEARCH, 2005, 25 (2B) : 1457 - 1463
  • [9] Breast cancer bone metastases: denosumab or zoledronic acid?
    Gabri van der Pluijm
    Nature Reviews Endocrinology, 2011, 7 : 134 - 135
  • [10] CANCER Breast cancer bone metastases: denosumab or zoledronic acid?
    van der Pluijm, Gabri
    NATURE REVIEWS ENDOCRINOLOGY, 2011, 7 (03) : 134 - 135
12345